Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 100.65K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | -6.61K | -190.49K | -174.84K | -154.68K | -97.42K | -3.39K |
EBITDA | -20.49M | -20.59M | -15.79M | -14.42M | -12.27M | -5.90M |
Net Income | -19.25M | -20.78M | -15.96M | -14.26M | -12.36M | -5.91M |
Balance Sheet | ||||||
Total Assets | 17.42M | 25.57M | 43.65M | 58.84M | 73.95M | 20.36M |
Cash, Cash Equivalents and Short-Term Investments | 15.90M | 24.01M | 41.30M | 55.20M | 70.73M | 19.23M |
Total Debt | 145.04K | 243.66K | 234.47K | 52.89K | 204.95K | 108.50K |
Total Liabilities | 4.90M | 4.38M | 2.74M | 2.80M | 2.38M | 660.84K |
Stockholders Equity | 12.52M | 21.19M | 40.91M | 56.04M | 71.57M | 19.70M |
Cash Flow | ||||||
Free Cash Flow | -17.87M | -17.83M | -14.37M | -12.80M | -10.61M | -5.67M |
Operating Cash Flow | -17.87M | -17.81M | -14.35M | -12.77M | -10.59M | -5.65M |
Investing Cash Flow | 10.96M | 3.37M | -930.21K | 179.27K | -19.53M | -16.14K |
Financing Cash Flow | 11.99K | 66.71K | -500.00K | -2.18M | 63.42M | 23.66M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $7.92B | -0.43 | -41.67% | 2.21% | 22.29% | -1.85% | |
48 Neutral | $61.73M | ― | -100.55% | ― | -100.00% | -22.09% | |
45 Neutral | $45.36M | ― | -88.59% | ― | ― | -8.47% | |
39 Underperform | $66.99M | ― | -150.82% | ― | ― | ― | |
38 Underperform | $84.62M | ― | 0.00% | ― | ― | ― | |
36 Underperform | $136.26M | ― | -73.46% | ― | ― | 62.69% | |
34 Underperform | $34.43M | ― | -44.71% | ― | ― | 44.85% |
On March 27, 2025, Lantern Pharma announced its financial results for the fourth quarter and full year ended December 31, 2024, alongside updates on its AI-driven drug candidates and operational progress. The company reported significant advancements in its clinical programs, including the HARMONIC™ trial for LP-300, which showed promising results in never-smoker NSCLC patients, and the continued progress of LP-184 and LP-284 in clinical trials. Lantern Pharma also highlighted its innovative AI capabilities, such as the RADR® platform surpassing 100 billion oncology-specific data points and the development of an AI-powered ADC module, which could significantly reduce development timelines and costs.